Skip to Content

Omeros Corporation

Securities Class Action

  • Date:
  • 10/7/2021
  • Company Name:
  • Omeros Corporation
  • Stock Symbol:
  • OMER
  • Status:
  • Investigating

Case Finder

Locate any case using the tools below.

NEW YORK, October 7, 2021 – Bragar Eagel & Squire, P.C., a nationally recognized stockholder rights law firm, is investigating potential claims against Omeros Corporation (“Omeros” or the “Company”) (NASDAQ: OMER) on behalf of Omeros stockholders. Our investigation concerns whether Omeros has violated the federal securities laws and/or engaged in other unlawful business practices.

On October 1, 2021, Omeros announced that the U.S. Food and Drug Administration (“FDA”) had identified deficiencies with the Company’s Biologics License Application for its drug candidate narsoplimab in the treatment of hematopoietic stem cell transplant-associated thrombotic microangiopathy (HSCT-TMA), which “preclude discussion of labeling and post-marketing requirements/commitments at this time.” Though the “FDA did not provide specific details of the deficiencies in its notification[,]” the Company stated that it "does not currently expect any resolution to occur by the October 17, 2021 target action date under the Prescription Drug User Fee Act (PDUFA).”

On this news, Omeros’s stock price fell $5.25 per share, or 38%, to close at $8.54 per share on October 1, 2021, thereby injuring investors.
 
The individual or institution below (“Plaintiff”) has reviewed and agrees to the Bragar Eagel & Squire, P.C. (“BESPC”) retainer agreement and authorizes BESPC to prosecute an action on Plaintiff’s behalf under the federal securities laws or applicable state laws to recover damages on behalf of investors in Omeros Corporation . BESPC will prosecute the action on a full contingency basis and will forward all costs and expenses.
 

Case Finder

Locate any case using the tools below.

You may share a link to this page on any of the sites listed below or send link via email: